

~ Contour Dermatology Seeks Participants for Two Clinical Studies ~

New Medications Offer Promise for People with Eczema and Psoriasis



Timothy M. Jochen, M.D

If you thought eczema was just an annoying rash, think again. Yes, it is irritating and frustrating, but even worse, patients can be hospitalized for this chronic skin condition and it can be emotionally debilitating for some.

Eczema affects about 15 million Americans. About 1 in 5 children are affected. Eczema usually begins in childhood and can persist into or reappear in adulthood.

The standard of care for eczema for years has been corticosteroid creams as a first-line treatment to reduce inflammation and itchiness and restore the protective barrier of the skin.



Eczema lesions.

New, Non-Steroidal Eczema Medication Study

I am honored and excited to have been selected as a principal investigator by Palmtree Clinical Research as the only trial site in the Coachella Valley for a new topical medication for eczema. Currently known as AN2728, this new medication is a plant-based, steroid-free topical ointment that works by inhibiting the chemokines which play a role in inflammation. It contains boron among its active ingredients and may help manage eczema with a better safety profile and fewer side effects than the current options. If approved by the FDA, it will be the first topical non-steroidal treatment that inhibits TNF-alpha release. There is no cost to participate in this Phase III



Plaque psoriasis.

clinical study which is open to children age 2 and above and adults with mild to moderate eczema. In fact, participants will receive reimbursement for their time and travel. As a blind, randomized trial, two-thirds of the participants will receive the new medication for 28 days and one third will receive a placebo.

Generic Psoriasis Medication Clinical Study

Characterized by thick patches of red or scaly skin, typically on the elbows, knees and genital area, there is no cure for psoriasis, but it can be managed effectively.

The second clinical trial for which Contour Dermatology is recruiting participants is a Phase III trial to compare the safety and effectiveness of a bio-similar version of generic adalimumab versus the brand name adalimumab (Humira) in patients with moderate to severe plaque-type psoriasis. Participants 18 years and older will receive either the generic or Humira by subcutaneous injection for 39 weeks at no cost.

Injectable biologic medications such as adalimumab are recommended when the patient does not respond well to topical or oral medications or when the condition is moderate to severe. However, biologic medications may not be covered some insurances and are extremely expensive. I am looking forward to the approval of the generic medication which could be an option for more patients.

If you are interested in either study, please call us at (760) 423-4000 to arrange for a pre-screening to find out if you meet the criteria.

Contour Dermatology Locations

Rancho Mirage	42-600 Mirage Road	Building A-1	760-423-4000
Palm Springs	1180 North Indian Canyon Drive	Suite E-419	760-423-4000
Santa Monica	2500 Broadway Avenue, Building F	Suite F-125	310-817-2662
Irvine	7545 Irvine Center Drive	Suite 200	949-682-8902

888-977-SKIN